Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Chimerix ( (CMRX) ) has shared an update.
Chimerix announced plans to submit a new drug application for dordaviprone, targeting recurrent H3 K27M-mutant diffuse glioma, aiming for accelerated FDA approval by the end of 2024. The company has engaged with the FDA extensively and achieved significant program milestones, including substantial enrollment in the Phase 3 ACTION study. If approved, this could position Chimerix as a leader in treating this aggressive form of glioma, potentially impacting market dynamics and offering new hope for patients with no current approved therapies.
More about Chimerix
Chimerix, Inc. operates in the pharmaceutical industry, focusing primarily on developing innovative therapeutics for cancer treatment. The company is notably working on novel compounds like dordaviprone and ONC206 targeting specific mutations in gliomas and central nervous system tumors, with a market focus on unmet medical needs such as rare pediatric diseases.
YTD Price Performance: -10.08%
Average Trading Volume: 509,936
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $77.79M
See more data about CMRX stock on TipRanks’ Stock Analysis page.
